A 48-year-old woman with poorly controlled type 1 diabetes mellitus undergoes fundoscopic examination and is found to have proliferative diabetic retinopathy (PDR) with vitreous hemorrhage. Which of the following is NOT an accepted treatment modality for PDR?

Explanation

## Proliferative Diabetic Retinopathy: Treatment Paradigm ### Current Evidence-Based Management **Key Point:** PDR is treated with laser photocoagulation, anti-VEGF therapy, or vitrectomy. Topical prostaglandin analogs are NOT a standard treatment for PDR and do not address the underlying neovascular pathology. ### Established Treatment Modalities for PDR | Modality | Mechanism | Indication | Evidence | |----------|-----------|-----------|----------| | **Panretinal Photocoagulation (PRP)** | Ablates ischemic retina, reduces VEGF production | First-line for PDR without macular edema | ETDRS landmark study; gold standard | | **Anti-VEGF Agents** (bevacizumab, aflibercept, ranibizumab) | Blocks vascular endothelial growth factor | PDR with or without DME; regression of NV | VIVID/VISTA, PROTOCOL S trials | | **Pars Plana Vitrectomy** | Removes vitreous hemorrhage; relieves tractional forces | Dense vitreous hemorrhage; tractional RD; combined PDR-DME | Standard surgical approach | | **Intravitreal Corticosteroids** | Anti-inflammatory; may reduce VEGF | Refractory DME or PDR with severe inflammation | Adjunctive role | ### Why Topical Prostaglandin Analogs Are NOT Used **High-Yield:** Topical prostaglandin analogs (latanoprost, travoprost, bimatoprost) are used exclusively for **glaucoma management** to lower intraocular pressure. They have: - No anti-VEGF activity - No effect on retinal neovascularization - No role in treating PDR - No systemic absorption sufficient to affect retinal vascular disease **Clinical Pearl:** Confusing topical prostaglandins with systemic or intravitreal therapies is a common trap. Always distinguish between: - **Topical agents** → IOP reduction (glaucoma) - **Intravitreal agents** → anti-VEGF or corticosteroid effect (retinal disease) ### Treatment Algorithm for PDR ```mermaid flowchart TD A[PDR Diagnosed]:::outcome --> B{Vitreous Hemorrhage?}:::decision B -->|No| C{Macular Edema?}:::decision B -->|Yes| D[Vitrectomy]:::action C -->|No| E[PRP or Anti-VEGF]:::action C -->|Yes| F[Anti-VEGF + PRP/Vitrectomy]:::action D --> G[Assess for NV regression]:::outcome E --> G F --> G G --> H{NV Resolved?}:::decision H -->|Yes| I[Observe + Glycemic Control]:::action H -->|No| J[Repeat PRP or Anti-VEGF]:::action ``` **Mnemonic for PDR Treatment:** **PAV** — **P**RP, **A**nti-VEGF, **V**itrectomy. [cite:Yanoff & Duker Ophthalmology 5e Ch 6; PROTOCOL S Trial]